Davis Polk advised the joint book-running managers in connection with a $460 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “TPTX.”

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Daniel Reichert and Dana Lueck-Mammen. The tax team included counsel Ethan R. Goldman and associate Erin van Wesenbeeck. The intellectual property and technology transactions team included counsel Daniel F. Forester. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post